Trevi Therapeutics reports promising results for Oral Nalbuphine in human abuse potential study

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced positive oral nalbuphine results from its human abuse potential (HAP) study evaluating the investigational therapy Haduvio™ for ... Read More